Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

125.02 -0.18 (-0.14%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
67 68 Next >
News headline image
Why Gilead Sciences Stock Slipped Today ↗
Via The Motley Fool
News headline image
How Is The Market Feeling About Gilead Sciences? ↗
 
Via Benzinga
News headline image
Wall Street Rally Pauses, Tesla Heads For Strongest Week In 6 Months: What's Driving Markets Friday? ↗
Wall Street's three-day rally came to a pause on Friday, with major indices hovering near the flatline by midday in New York as caution returned amid mixed signals on U.S.-China trade relations. 
Via Benzinga
News headline image
Earnings Scheduled For April 24, 2025 ↗
 
Via Benzinga
News headline image
P/E Ratio Insights for Gilead Sciences ↗
 
Via Benzinga
News headline image
Get insights into the top movers in the S&P500 index of Friday's pre-market session. ↗
Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session. 
Via Chartmill
News headline image
AbbVie Reports Upbeat Q1 Earnings, Raises 2025 Earnings Forecast: Retail’s Elated ↗
The company’s immunology drugs, Skyrizi and Rinvoq, marked significant revenue growth, offsetting a 50.6% decrease in net revenue from its arthritis drug, Humira. 
Via Stocktwits
Topics World Trade
News headline image
Gilead Sciences Q1 Earnings Surpass Analyst Expectations, But Revenue Falls Short Of Estimates: Retail’s Optimistic ↗
The company is eyeing FDA approval for its drug, lenacapavir, for HIV prevention by mid-June. 
Via Stocktwits
Topics Government Stocks
News headline image
Skechers Posts Weak Revenue, Joins Intel, Gilead Sciences And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Coursera Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Alphabet, Intel And 3 Stocks To Watch Heading Into Friday ↗
 
Via Benzinga
News headline image
Which S&P500 stocks are moving after the closing bell on Thursday? ↗
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top S&P500 gainers and losers in today's after-hours session. 
Via Chartmill
News headline image
Gilead (GILD) Q1 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings World Trade
News headline image
Gilead Sciences Stock Slips After Mixed Q1 Results, Lowered FY25 EPS Guidance ↗
Gilead Sciences releases its first-quarter results after Thursday's closing bell. Here's a look at the details from the report. 
Via Benzinga
News headline image
Gilead Sciences (NASDAQ:GILD) Misses Q1 Revenue Estimates
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $6.67 billion. The company’s full-year revenue guidance... 
Via StockStory
Topics Artificial Intelligence
News headline image
Gilead Sciences' Bread-And-Butter Drug Missed Sales Views. And It's Not The Only One. ↗
Biktarvy sales came in below forecasts. Will Gilead stock be able to shrug it off? 
Via Investor's Business Daily
News headline image
Gilead Sciences Announces First Quarter 2025 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Wall Street Rally Extends Into Third Day: What's Driving Markets Thursday? ↗
U.S. equities are pushing higher for a third straight session, eyeing the longest winning streak since the Trump tariff announcement on April 2, as optimism over corporate earnings and easing trade... 
Via Benzinga
Topics Government World Trade
News headline image
Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher ↗
BriaCell confirms complete resolution of lung metastasis at 4 months in Phase 1/2a trial using Bria-OTS immunotherapy in advanced breast cancer. 
Via Benzinga
News headline image
Gilead Sciences's Options Frenzy: What You Need to Know ↗
 
Via Benzinga
News headline image
Exploring Gilead Sciences's Earnings Expectations ↗
 
Via Benzinga
News headline image
Gilead Sciences (GILD) To Report Earnings Tomorrow: Here Is What To Expect
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
News headline image
Assessing Gilead Sciences: Insights From 15 Financial Analysts ↗
 
Via Benzinga
News headline image
Gilead Cancer Drug Combined With Merck's Drug Effective In Difficult To Treat Type Of Breast Cancer ↗
Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with no new safety concerns. 
Via Benzinga
News headline image
Gilead Announces Positive Results From Trodelvy-Keytruda Combo Study For Breast Cancer: But Retail’s Unmoved ↗
Triple-negative breast cancer accounts for approximately 15% of all breast cancers and has a higher chance of recurrence. 
Via Stocktwits
News headline image
Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Why Quality Investors May Find GILEAD SCIENCES INC (NASDAQ:GILD) Attractive. ↗
A fundamental analysis of (NASDAQ:GILD) shows GILEAD SCIENCES INC (NASDAQ:GILD) may be suited for quality investing, we'll explore why in this article. 
Via Chartmill
News headline image
2 High-Yielding ETFs Retirees Can Safely Build Their Portfolios Around ↗
Via The Motley Fool
Topics ETFs Economy World Trade
News headline image
Time 100 Most Influential People Includes Elon Musk, Mark Zuckerberg, Alex Karp And More Public Company CEOs ↗
The Time 100 list of the most influential people in the world includes Elon Musk, Mark Zuckerberg and several other CEOs of publicly traded companies. 
Via Benzinga
News headline image
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction ↗
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating... 
Via Benzinga
Topics Government
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
67 68 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.